Drugs of today
-
Migraine is a common, painful and highly disabling neurological condition that has plagued mankind for millennia, but its pathophysiology remained largely obscure until recently. The clinical success of triptans for treating migraine and the discovery that calcitonin gene-related peptide (CGRP) plays a prominent role in migraine led to increased research interest into this disease. An important improvement has been the development of monoclonal antibodies, including galcanezumab, that bind to CGRP or to its receptor, preventing its activation. ⋯ Galcanezumab is approved for the prevention of migraine in the U. S., the European Union, Canada and Mexico, and was also approved for the treatment of episodic cluster headache in the U. S.